Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MET overexpression
i
Other names:
DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4233
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
MET exon 14 mutation (33)
MET mutation (13)
MET H1094Y (3)
MET N375S (3)
EGFR mutation + MET mutation (2)
MET D1010N (2)
MET D1228N (2)
MET D1228V (2)
MET F1200I (2)
MET exon 14 mutation + EGFR exon 20 insertion (2)
EGFR T790M + MET mutation (1)
EGFR exon 21 deletion + EGFR L858R + MET Exon 14 mutation (1)
EGFR mutation + MET Y1003N (1)
EGFR wild-type + MET wild-type (1)
MET D1010H (1)
MET D1010Y (1)
MET D1028N (1)
MET R1004G (1)
MET Y1003C (1)
MET Y1021H (1)
MET Y1230C (1)
MET exon 14 mutation + KRAS G12A (1)
MET exon 14 mutation + TP53 mutation (1)
MET mutation + AXL mutation (1)
MET D1228Y (0)
MET exon 14 skipping mutation + EGFR G709T (0)
MET D1228H (0)
MET Y1230C (0)
ROS rearrangement + MET D1246N (0)
MET exon 14 mutation (33)
MET mutation (13)
MET H1094Y (3)
MET N375S (3)
EGFR mutation + MET mutation (2)
MET D1010N (2)
MET D1228N (2)
MET D1228V (2)
MET F1200I (2)
MET exon 14 mutation + EGFR exon 20 insertion (2)
EGFR T790M + MET mutation (1)
EGFR exon 21 deletion + EGFR L858R + MET Exon 14 mutation (1)
EGFR mutation + MET Y1003N (1)
EGFR wild-type + MET wild-type (1)
MET D1010H (1)
MET D1010Y (1)
MET D1028N (1)
MET R1004G (1)
MET Y1003C (1)
MET Y1021H (1)
MET Y1230C (1)
MET exon 14 mutation + KRAS G12A (1)
MET exon 14 mutation + TP53 mutation (1)
MET mutation + AXL mutation (1)
MET D1228Y (0)
MET exon 14 skipping mutation + EGFR G709T (0)
MET D1228H (0)
MET Y1230C (0)
ROS rearrangement + MET D1246N (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MET overexpression
Non Small Cell Lung Cancer
MET overexpression
Non Small Cell Lung Cancer
MYTX-011
Sensitive: B - Late Trials
MYTX-011
Sensitive
:
B
MYTX-011
Sensitive: B - Late Trials
MYTX-011
Sensitive
:
B
MET overexpression
Non Small Cell Lung Cancer
MET overexpression
Non Small Cell Lung Cancer
gumarontinib
Sensitive: C2 – Inclusion Criteria
gumarontinib
Sensitive
:
C2
gumarontinib
Sensitive: C2 – Inclusion Criteria
gumarontinib
Sensitive
:
C2
MET overexpression
Lung Non-Squamous Non-Small Cell Cancer
MET overexpression
Lung Non-Squamous Non-Small Cell Cancer
ABBV-399
Sensitive: C2 – Inclusion Criteria
ABBV-399
Sensitive
:
C2
ABBV-399
Sensitive: C2 – Inclusion Criteria
ABBV-399
Sensitive
:
C2
MET overexpression
Non Small Cell Lung Cancer
MET overexpression
Non Small Cell Lung Cancer
tepotinib
Sensitive: C2 – Inclusion Criteria
tepotinib
Sensitive
:
C2
tepotinib
Sensitive: C2 – Inclusion Criteria
tepotinib
Sensitive
:
C2
MET overexpression
Non Small Cell Lung Cancer
MET overexpression
Non Small Cell Lung Cancer
osimertinib + savolitinib
Sensitive: C2 – Inclusion Criteria
osimertinib + savolitinib
Sensitive
:
C2
osimertinib + savolitinib
Sensitive: C2 – Inclusion Criteria
osimertinib + savolitinib
Sensitive
:
C2
MET overexpression
Non Small Cell Lung Cancer
MET overexpression
Non Small Cell Lung Cancer
erlotinib + ARQ 197
Sensitive: C3 – Early Trials
erlotinib + ARQ 197
Sensitive
:
C3
erlotinib + ARQ 197
Sensitive: C3 – Early Trials
erlotinib + ARQ 197
Sensitive
:
C3
MET overexpression
Gastric Cancer
MET overexpression
Gastric Cancer
ARQ 197
Sensitive: C3 – Early Trials
ARQ 197
Sensitive
:
C3
ARQ 197
Sensitive: C3 – Early Trials
ARQ 197
Sensitive
:
C3
MET overexpression
Melanoma
MET overexpression
Melanoma
vemurafenib
Resistant: C3 – Early Trials
vemurafenib
Resistant
:
C3
vemurafenib
Resistant: C3 – Early Trials
vemurafenib
Resistant
:
C3
MET overexpression
Colorectal Cancer
MET overexpression
Colorectal Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR inhibitor
Resistant
:
C3
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR inhibitor
Resistant
:
C3
MET overexpression
Glioblastoma
MET overexpression
Glioblastoma
bevacizumab
Resistant: C3 – Early Trials
bevacizumab
Resistant
:
C3
bevacizumab
Resistant: C3 – Early Trials
bevacizumab
Resistant
:
C3
MET overexpression
Hepatocellular Cancer
MET overexpression
Hepatocellular Cancer
tepotinib
Sensitive: C3 – Early Trials
tepotinib
Sensitive
:
C3
tepotinib
Sensitive: C3 – Early Trials
tepotinib
Sensitive
:
C3
MET overexpression
Gastric Cancer
MET overexpression
Gastric Cancer
crizotinib
Sensitive: C3 – Early Trials
crizotinib
Sensitive
:
C3
crizotinib
Sensitive: C3 – Early Trials
crizotinib
Sensitive
:
C3
MET overexpression
Gastric Cancer
MET overexpression
Gastric Cancer
savolitinib
Sensitive: C3 – Early Trials
savolitinib
Sensitive
:
C3
savolitinib
Sensitive: C3 – Early Trials
savolitinib
Sensitive
:
C3
MET overexpression
Non Small Cell Lung Cancer
MET overexpression
Non Small Cell Lung Cancer
REGN5093
Sensitive: C3 – Early Trials
REGN5093
Sensitive
:
C3
REGN5093
Sensitive: C3 – Early Trials
REGN5093
Sensitive
:
C3
MET overexpression
Non Small Cell Lung Cancer
MET overexpression
Non Small Cell Lung Cancer
BPI-9016M
Sensitive: C3 – Early Trials
BPI-9016M
Sensitive
:
C3
BPI-9016M
Sensitive: C3 – Early Trials
BPI-9016M
Sensitive
:
C3
MET overexpression
Squamous Cell Carcinoma of Head and Neck
MET overexpression
Squamous Cell Carcinoma of Head and Neck
cetuximab + AV-299
Sensitive: C3 – Early Trials
cetuximab + AV-299
Sensitive
:
C3
cetuximab + AV-299
Sensitive: C3 – Early Trials
cetuximab + AV-299
Sensitive
:
C3
MET overexpression
Non Small Cell Lung Cancer
MET overexpression
Non Small Cell Lung Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
MET overexpression
Pancreatic Cancer
MET overexpression
Pancreatic Cancer
cetuximab
Resistant: C4 – Case Studies
cetuximab
Resistant
:
C4
cetuximab
Resistant: C4 – Case Studies
cetuximab
Resistant
:
C4
MET overexpression
Pancreatic Cancer
MET overexpression
Pancreatic Cancer
trametinib + dabrafenib
Resistant: C4 – Case Studies
trametinib + dabrafenib
Resistant
:
C4
trametinib + dabrafenib
Resistant: C4 – Case Studies
trametinib + dabrafenib
Resistant
:
C4
MET overexpression
Pancreatic Cancer
MET overexpression
Pancreatic Cancer
TR1801-ADC
Sensitive: D – Preclinical
TR1801-ADC
Sensitive
:
D
TR1801-ADC
Sensitive: D – Preclinical
TR1801-ADC
Sensitive
:
D
MET overexpression
Adrenal Cortex Carcinoma
MET overexpression
Adrenal Cortex Carcinoma
cabozantinib capsule
Sensitive: D – Preclinical
cabozantinib capsule
Sensitive
:
D
cabozantinib capsule
Sensitive: D – Preclinical
cabozantinib capsule
Sensitive
:
D
MET overexpression
Lung Adenocarcinoma
MET overexpression
Lung Adenocarcinoma
CKD-702
Sensitive: D – Preclinical
CKD-702
Sensitive
:
D
CKD-702
Sensitive: D – Preclinical
CKD-702
Sensitive
:
D
MET overexpression
Melanoma
MET overexpression
Melanoma
BRAF inhibitor + MEK inhibitor
Resistant: D – Preclinical
BRAF inhibitor + MEK inhibitor
Resistant
:
D
BRAF inhibitor + MEK inhibitor
Resistant: D – Preclinical
BRAF inhibitor + MEK inhibitor
Resistant
:
D
MET overexpression
Hepatocellular Cancer
MET overexpression
Hepatocellular Cancer
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
MET overexpression
Gastric Cancer
MET overexpression
Gastric Cancer
tepotinib
Sensitive: D – Preclinical
tepotinib
Sensitive
:
D
tepotinib
Sensitive: D – Preclinical
tepotinib
Sensitive
:
D
MET overexpression
Non Small Cell Lung Cancer
MET overexpression
Non Small Cell Lung Cancer
crizotinib + chidamide
Sensitive: D – Preclinical
crizotinib + chidamide
Sensitive
:
D
crizotinib + chidamide
Sensitive: D – Preclinical
crizotinib + chidamide
Sensitive
:
D
MET overexpression
Non Small Cell Lung Cancer
MET overexpression
Non Small Cell Lung Cancer
MG132
Sensitive: D – Preclinical
MG132
Sensitive
:
D
MG132
Sensitive: D – Preclinical
MG132
Sensitive
:
D
MET overexpression
Gastric Cancer
MET overexpression
Gastric Cancer
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
MET overexpression
Gastric Cancer
MET overexpression
Gastric Cancer
S95027
Sensitive: D – Preclinical
S95027
Sensitive
:
D
S95027
Sensitive: D – Preclinical
S95027
Sensitive
:
D
MET overexpression
Hepatocellular Cancer
MET overexpression
Hepatocellular Cancer
SHR-A1403
Sensitive: D – Preclinical
SHR-A1403
Sensitive
:
D
SHR-A1403
Sensitive: D – Preclinical
SHR-A1403
Sensitive
:
D
MET overexpression
Pancreatic Cancer
MET overexpression
Pancreatic Cancer
SHR-A1403
Sensitive: D – Preclinical
SHR-A1403
Sensitive
:
D
SHR-A1403
Sensitive: D – Preclinical
SHR-A1403
Sensitive
:
D
MET overexpression
Non Small Cell Lung Cancer
MET overexpression
Non Small Cell Lung Cancer
SHR-A1403
Sensitive: D – Preclinical
SHR-A1403
Sensitive
:
D
SHR-A1403
Sensitive: D – Preclinical
SHR-A1403
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login